The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia

Blood

Volumn 103, Issue 7, 2004, Pages 2802-2805

  Cools, Jan ^a   Quentmeier, Hilmar ^b   Huntly, Brian J P ^b   Marynen, Peter ^b   Griffin, James D ^b   Drexler, Hans G ^b   Gilliland, D Gary ^b  

^a CENTER FOR HUMAN GENETICS   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; IMATINIB; KINASE FIP1L1; MIDOSTAURIN; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR A; SU 5614; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN; CELL STRAIN EOL 1; CHRONIC LEUKEMIA; CONTROLLED STUDY; DRUG EFFECT; EOSINOPHILIC LEUKEMIA; IN VITRO STUDY; LEUKEMIA CELL LINE; LEUKEMOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 1642324059     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2479     Document Type: Article

References (20)

1. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975;54:1-27.
2. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994;83:2759-2779.
3. Bain BJ. Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome. Br J Haematol. 1996;95:2-9.
4. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
5. Drexler HG, Matsuo AY, MacLeod RA. Continuous hematopoietic cell lines as model systems for leukemia-lymphoma research. Leuk Res. 2000;24:881-911.
6. Quentmeier H, Reinhardt J, Zaborski M, Drexler HG. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia. 2003;17:120-124.
7. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003;101:4660-4666.
8. Saito H, Bourinbaiar A, Ginsburg M, et al. Establishment and characterization of a new human eosinophilic leukemia cell line. Blood. 1985;66:1233-1240.
9. Quentmeier H, Reinhardt J, Zaborski M, Drexler HG. MLL partial tandem duplication in acute leukemia cell lines. Leukemia. 2003;17:980-981.
10. Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene. 2001;20:5695-5707.
11. Caligiud MA, Strout MP, Schichman SA, et al. Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res. 1996;56:1418-1425.
12. Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet. 2002;3:179-198.
13. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002;1:493-502.
14. Andrejauskas-Buchdunger E, Regenass U. Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251. Cancer Res. 1992;52:5353-5358.
15. Cools J, Stover EH, Boulton CL, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR-induced myeloproliferative disease. Cancer Cell. 2003;3:459-469.
16. Sun L, Tran N, Tang F, et al. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J Med Chem. 1998;41:2588-2603.
17. Yee KW, O'Farrell AM, Smolich BD, et al. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood. 2002;100:2941-2949.
18. Spiekermann K, Dirschinger RJ, Schwab R, et al. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood. 2003;101:1494-1504.
19. Griffin JH, Leung J, Bruner RJ, Caligiud MA, Briesewitz R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A. 2003;100:7830-7835.
20. Higuchi W, Koike T, Ihizumi T, Shibata A. Hypereosinophilic syndrome terminating in acute myelogenous leukemia. Acta Haematol. 1993;90:165-166.